Lipigon Pharmaceuticals (LPGO) Q2 2024 earnings summary

Executive summary

• Focus on lipid-related diseases remains strong, with external validation for Lipisense's ANGPTL4 target from major industry players and investors.

• Key milestone payment of $1M USD received from Leaderna for Lipisense® Phase I bridging study approval in China.

• Partnership established with University of Washington for advanced lung injury studies.

• Patient recruitment ongoing for Phase II Lipisense® study, with expanded inclusion criteria to accelerate enrollment.

Financial highlights

• Net sales for Jan–Jun 2024: 8,970 tkr, down from 16,050 tkr year-over-year, mainly due to milestone timing.

• Operating result Jan–Jun 2024: -7,771 tkr (290 tkr in 2023); Q2 operating result: -357 tkr (7,134 tkr in Q2 2023).

• Net result Jan–Jun 2024: -7,830 tkr (297 tkr in 2023); Q2 net result: -415 tkr (7,133 tkr in Q2 2023).

• Cash and cash equivalents at June 30, 2024: 19,477 tkr (17,309 tkr in 2023).

• Equity at June 30, 2024: 25,244 tkr (27,588 tkr in 2023); equity per share: 0.17 kr (0.34 kr in 2023).

Outlook and guidance

• Resources focused on advancing Phase II Lipisense® study and preparing for further clinical development.

• Confident in patient recruitment due to expanded criteria and additional study centers.